Share on StockTwits
 

Cepheid (NASDAQ:CPHD) posted its quarterly earnings results on Friday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.04, AnalystRatingsNetwork reports. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million.

A number of research firms have recently commented on CPHD. Analysts at JPMorgan Chase & Co. downgraded shares of Cepheid from an “overweight” rating to a “neutral” rating in a research note to investors on Tuesday, January 7th. On a related note, analysts at Needham & Company initiated coverage on shares of Cepheid in a research note to investors on Thursday, December 19th. They set a “hold” rating on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Cepheid in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.16.

Cepheid (NASDAQ:CPHD) opened at 47.27 on Friday. Cepheid has a 52-week low of $30.95 and a 52-week high of $49.97. The stock’s 50-day moving average is $46.7 and its 200-day moving average is $40.72. The company’s market cap is $3.207 billion.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.